Golgi protein 73(GP73), a useful serum marker in liver diseases

2011 ◽  
Vol 49 (8) ◽  
Author(s):  
Xiangyi Liu ◽  
Xiaohua Wan ◽  
Zhongwu Li ◽  
Changqing Lin ◽  
Yutao Zhan ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Hepatitis B ◽  
Liver Diseases ◽  
Serum Marker ◽  
Serum Markers ◽  
Healthy Controls ◽  
B Virus ◽  
Different Types ◽  
Golgi Protein

AbstractThis study was performed to quantify the expression of Golgi protein-73 (GP73) in healthy controls and in patients with liver disease, and to evaluate the correlations between GP73 and other serum markers in different liver diseases.Serum GP73 was measured in 478 healthy controls and 296 patients with different types of liver disease. Quantitative hepatitis B virus (HBV) DNA was determined in two chronic hepatitis B (CHB) groups. Other serum liver fibrosis markers were measured in the liver fibrosis group and α-fetoprotein (AFP) was measured in hepatocellular carcinoma (HCC) group. The correlations between GP73 and these markers were evaluated.The GP73 value in hepatitis B e antigen (HBeAg)-positive CHB group, HBeAg-negative CHB group, liver fibrosis group and HCC group was significantly higher (p<0.001) than that in healthy controls. GP73 showed significant correlation with other markers in the liver fibrosis group and with AFP in the HCC group.Compared with healthy controls, GP73 in patients with liver disease was significantly increased. With the progression of liver disease, GP73 showed a significantly increasing trend. These results suggest that GP73 might be used as a serum marker for the diagnosis of liver diseases and for monitoring disease progression.

Noninvasive Markers of Liver Fibrosis and Inflammation in Chronic Hepatitis B-Virus Related Liver Disease

2006 ◽  
Vol 101 (11) ◽  
pp. 2537-2545 ◽  
Author(s):  
Mehdi Mohamadnejad ◽  
Ghodrat Montazeri ◽  
Atoosa Fazlollahi ◽  
Farhad Zamani ◽  
Jafar Nasiri ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis B Virus ◽  
Liver Fibrosis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Chronic Hepatitis B Virus ◽  
B Virus ◽  
Noninvasive Markers ◽  
Related Liver Disease

scholarly journals SIX1/EYA1 are novel liver damage biomarkers in chronic hepatitis B and other liver diseases

2020 ◽  
Author(s):  
Baoyan Xu ◽  
Zhiqiao Zhang ◽  
Chong Zheng ◽  
Yingzi Tang ◽  
Zhaoxia Tan ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Liver Damage ◽  
Liver Diseases ◽  
Serum Levels ◽  
Immunofluorescent Staining ◽  
Enzyme Linked Immunosorbent Assay ◽  
Healthy Controls

Abstract Background: The aim of this study was to investigate the clinicopathological significance of SIX1/ EYA1 in chronic hepatitis B (CHB) and other liver diseases. Materials and methods: Both SIX1 and EYA1 levels were detected in human serum and liver tissues by enzyme linked immunosorbent assay (ELISA) and immunofluorescent staining, respectively. Results: Serum SIX1 and EYA1 levels were 7.24±0.11 ng/ml and 25.21±0.51 ng/ml, respectively, in 313 CHB patients, and these values were significantly higher than those in 33 healthy controls (2.84±0.15ng/ml and 13.11±1.01ng/ml, respectively; P < 0.05). Serum SIX1 and EYA1 were also significantly increased in patients with many other liver diseases including liver fibrosis, hepatocellular carcinoma, fatty liver disease, alcoholic liver disease, fulminant hepatic failure, autoimmune liver disease, and hepatitis C relative to healthy controls ( P < 0.05). Dynamic observation of these proteins over time in 35 selected CHB patients revealed that SIX1 and EYA1 serum levels increased over an interval. Immunofluorescent staining revealed that both SIX1 and EYA1 were only expressed in hepatic stellate cells (HSCs), and their increased expression was evident in CHB liver tissue. Conclusion: Both SIX1 and EYA1 are novel biomarkers of liver damage in CHB and other liver diseases, with potential clinical utility.

scholarly journals Identification and Validation of Novel Biomarkers for HBV-Associated Hepatocellular Carcinoma, Liver Fibrosis/Cirrhosis and Chronic Hepatitis: A Case Control Study

2021 ◽  
Author(s):  
Dandan Zhao ◽  
Xiaoxiao Zhang ◽  
Yuhui Tang ◽  
Peilin Guo ◽  
Rong Ai ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Liver Fibrosis ◽  
Hepatitis B ◽  
Liver Diseases ◽  
Adaptor Protein ◽  
Healthy Controls ◽  
Qrt Pcr ◽  
Increasing Trend ◽  
Liver Tissues

Abstract BackgroundAt present, there are no accurate diagnostic biomarkers for distinguishing among hepatitis B virus (HBV)-related liver diseases. This research aimed to identify and validate a novel biomarker panel in patients with HBV-related hepatocellular carcinoma (HCC), liver fibrosis/liver cirrhosis (LF/LC) and chronic hepatitis B (CHB).MethodsTranscriptomics sequencing was conducted on a total of 19 liver tissues of the four groups. The hub mRNAs were identified using weighted gene co-expression network analysis (WGCNA) and short time-series expression miner (STEM) method. The expression levels of selected mRNAs and proteins were assessed by quantitative real-time polymerase chain reaction (qRT-PCR) using both liver tissues and peripheral blood mononuclear cells (PBMCs) and immunohistochemical (IHC) staining in liver tissues, respectively. Then, the expression activities of the screened targets were detected by enzyme-linked immunosorbent assay (ELISA) using the plasma samples from 200 and 400 subjects in the validation and testing sets, respectively. Finally, receiver operating characteristic (ROC) curve analysis was carried out to evaluate the diagnostic performance of each mRNA biomarker.ResultsSTEM analysis revealed 25 mRNAs exhibited an increasing trend in the four groups; while 9 hub mRNAs were identified by using WGCNA. Of note, the results of qRT-PCR and immunohistochemical analyses demonstrated that SHC adaptor protein 1 (SHC1), SLAM family member 8 (SLAMF8), and interleukin-32 (IL-32) exhibited a gradually increasing trend in the four groups. Subsequent ELISA tests on the validation cohort demonstrated that the plasma levels of SHC1, SLAMF8 and IL-32 were remarkably elevated in HCC group compared to the remaining three groups. Furthermore, a diagnostic model APFSSI (age, PLT, ferritin, SHC1, SLAMF8 and IL-32) was established to distinguish HCC from LF/LC (AUC=0.904), LF/LC from CHB (AUC=0.924), and CHB from healthy controls (AUC=0.966). Finally, the results in the test set were consistent with those in the validation set. ConclusionsSHC1, SLAMF8 and IL-32 can differentiate among HCC patients, LF/LC patients, CHB patients and healthy controls. More importantly, the combination of age, PLT, ferritin, SHC1, SLAMF8, and IL-32 (APFSSI model) greater improves the diagnostic accuracy of HBV-associated liver diseases.

scholarly journals Hepatocyte Membrane-Bound IgG and Circulating Liver-Specific Autoantibodies in Chronic Liver Disease: Relation to Hepatitis B Virus Serum Markers and Liver Histology

Hepatology ◽  
2007 ◽  
Vol 3 (2) ◽  
pp. 155-161 ◽  
Author(s):  
Riccardo Meliconi ◽  
Federico Miglio ◽  
M. Valeria Stancari ◽  
Mario Baraldini ◽  
G. Francesco Stefanini ◽  
...  
Keyword(s):  
Liver Disease ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Chronic Liver Disease ◽  
Serum Markers ◽  
Chronic Liver ◽  
Liver Histology ◽  
B Virus ◽  
Membrane Bound

scholarly journals Comparison and Validation of APRI and FIB-4 for Evaluating Liver Fibrosis in Chinese Hepatitis B Virus-infected Patients with Persistently Normal ALT, Mildly and Significantly Elevated ALT

2021 ◽  
Author(s):  
Shanshan Chen ◽  
Yuhan Gong ◽  
Jie Li ◽  
Xuan Dai ◽  
Yueyue Zhao ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Hepatitis B ◽  
Liver Biopsy ◽  
Serum Markers ◽  
Advanced Fibrosis ◽  
Significant Fibrosis ◽  
Biopsy Specimens ◽  
B Virus ◽  
Normal Alt ◽  
Noninvasive Markers

Abstract Background: Many noninvasive models based on serum markers composition are used for the assessment of liver fibrosis, reducing the need for liver biopsy. However, most of the models have rarely been validated in Chinese hepatitis B patients. We aim to evaluate and validate chronic hepatitis B(CHB) patients with normal ALT, mildly and significantly elevated ALT levels.Methods: This single-center retrospective study enrolled 285 patients with CHB who underwent liver biopsy. There were 156 patients in normal ALT group, 85 patients in mildly elevated ALT group, and 44 patients in significantly elevated ALT group. The diagnostic accuracy of APRI and FIB-4 was evaluated by areas under the characteristic curves (AUROC) using the histological assessment of the fibrosis stages of the biopsy specimens as the standards.Results: Among 285 patients with CHB, 156 patients had normal ALT level, of which 65 (41.7%) had significant fibrosis(S2-4). The evaluation of significant fibrosis, AUROC in APRI and FIB-4 were 0.608, 0.634, 0.708 and 0.638, 0.679, 0.734 in normal ALT, mildly and significantly elevated ALT, respectively. The assessment of advanced fibrosis, AUROC in APRI and FIB-4 were 0.636, 0.751, 0.708 and 0.652, 0.763, 0.734 in normal ALT, mildly and significantly elevated ALT groups, respectively. Conclusions: APRI and FIB-4 may not be ideal noninvasive markers for evaluating liver fibrosis in Chinese HBV-infected patients with normal ALT levels. Compared with HBV-infected patients with normal ALT, APRI and FIB-4 had high accuracies in diagnosing liver fibrosis in patients with mildly and significantly elevated ALT.

Precore/Core Promoter Mutant Hepatitis B Virus Produces More Severe Histologic Liver Disease than Wild Type Hepatitis B Virus

2007 ◽  
Vol 1 (1) ◽  
pp. 41-46 ◽  
Author(s):  
Mamun-Al-Mahtab ◽  
Salimur Rahman ◽  
Mobin Khan ◽  
Ayub Mamun ◽  
Kamal
Keyword(s):  
Liver Disease ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Core Promoter ◽  
Wild Type ◽  
B Virus ◽  
Promoter Mutant
Sign in / Sign up

Export Citation Format

Share Document